Literature DB >> 21134399

A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament "hook" effect.

Ching-Hua Lu1, Bernadett Kalmar, Andrea Malaspina, Linda Greensmith, Axel Petzold.   

Abstract

INTRODUCTION: Neurofilament (Nf) aggregates are a common pathological feature of neurodegenerative disorders. Although Nf levels have been investigated as a potential disease biomarker, Nf aggregates may mask Nf epitopes, preventing accurate quantification by immunoassay. Using the SOD1(G93A) mouse model of amyotrophic lateral sclerosis, we developed a method to disrupt Nf aggregates, allowing optimal immunoassay performance.
METHODS: Phosphorylated (NfH(SMI35)) and hyperphosphorylated (NfH(SMI34)) Nf levels in plasma from 120-day SOD1(G93A) mice were quantified using an in-house ELISA modified for use with small volumes. Different pre-analytical methods were tested for their ability to solubilize Nf aggregates and immunoblotting was used for qualitative analysis.
RESULTS: A 'hook effect' was observed for serially diluted plasma samples quantified using an ELISA originally developed for CSF samples. Immunoblotting confirmed the existence of high molecular-weight NfH aggregates in plasma and the resolving effect of timed urea on these aggregates. Thermostatic (pre-thawing) and chemical (calcium chelators, urea) pre-analytical processing of samples had variable success in disrupting NfH aggregates. Timed urea-calcium chelator incubation yielded the most consistent plasma NfH levels. A one hour sample pre-incubation with 0.5M urea in Barbitone-EDTA buffer at room temperature resolved the "hook effect" without compromising the ELISA. In SOD1(G93A) mice, median levels of NfH(SMI34) were over 10-fold and NfH(SMI35) levels 5-fold greater than controls.
CONCLUSION: NfH aggregates can be solubilised and the "hook effect" abolished by a one-hour sample pre-incubation in a urea-calcium chelator-enriched buffer. This method is applicable for quantification of NfH phosphoforms in experimental and disease settings where Nf aggregate formation occurs.
© 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21134399     DOI: 10.1016/j.jneumeth.2010.11.026

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  23 in total

1.  Large molecule specific assay operation: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team.

Authors:  Lauren Stevenson; Marian Kelley; Boris Gorovits; Clare Kingsley; Heather Myler; Karolina Osterlund; Arumugam Muruganandam; Yoshiyuki Minamide; Mario Dominguez
Journal:  AAPS J       Date:  2013-11-16       Impact factor: 4.009

2.  Protein aggregate formation permits millennium-old brain preservation.

Authors:  Axel Petzold; Ching-Hua Lu; Mike Groves; Johan Gobom; Henrik Zetterberg; Gerry Shaw; Sonia O'Connor
Journal:  J R Soc Interface       Date:  2020-01-08       Impact factor: 4.118

3.  Dysregulated expression and distribution of Kif5α in neurites of wobbler motor neurons.

Authors:  Kilian Kürten; Anne-Christin Gude; Aimo Samuel Christian Epplen; Jan Stein; Carsten Theiss; Veronika Matschke
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

4.  Analysis of circulating protein aggregates as a route of investigation into neurodegenerative disorders.

Authors:  Rocco Adiutori; Fabiola Puentes; Michael Bremang; Vittoria Lombardi; Irene Zubiri; Emanuela Leoni; Johan Aarum; Denise Sheer; Simon McArthur; Ian Pike; Andrea Malaspina
Journal:  Brain Commun       Date:  2021-07-09

5.  Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS.

Authors:  Ching-Hua Lu; Axel Petzold; Bernadett Kalmar; James Dick; Andrea Malaspina; Linda Greensmith
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

6.  Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.

Authors:  Ching-Hua Lu; Corrie Macdonald-Wallis; Elizabeth Gray; Neil Pearce; Axel Petzold; Niklas Norgren; Gavin Giovannoni; Pietro Fratta; Katie Sidle; Mark Fish; Richard Orrell; Robin Howard; Kevin Talbot; Linda Greensmith; Jens Kuhle; Martin R Turner; Andrea Malaspina
Journal:  Neurology       Date:  2015-05-01       Impact factor: 9.910

7.  The diagnostic and prognostic value of neurofilament heavy chain levels in immune-mediated optic neuropathies.

Authors:  Axel Petzold; Gordon T Plant
Journal:  Mult Scler Int       Date:  2012-12-17

8.  CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome.

Authors:  M Khalil; C Enzinger; C Langkammer; S Ropele; A Mader; A Trentini; M L G Vane; M Wallner-Blazek; G Bachmaier; J-J Archelos; M J A Koel-Simmelink; M A Blankenstein; S Fuchs; F Fazekas; C E Teunissen
Journal:  Mult Scler       Date:  2012-08-23       Impact factor: 6.312

9.  Detection of non-PCR amplified S. enteritidis genomic DNA from food matrices using a gold-nanoparticle DNA biosensor: a proof-of-concept study.

Authors:  Sylvia A Vetrone; Michael C Huarng; Evangelyn C Alocilja
Journal:  Sensors (Basel)       Date:  2012-08-02       Impact factor: 3.576

10.  Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study.

Authors:  Ching-Hua Lu; Axel Petzold; Jo Topping; Kezia Allen; Corrie Macdonald-Wallis; Jan Clarke; Neil Pearce; Jens Kuhle; Gavin Giovannoni; Pietro Fratta; Katie Sidle; Mark Fish; Richard Orrell; Robin Howard; Linda Greensmith; Andrea Malaspina
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-07-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.